Guest Column: Don't Let These 2 Quality Nightmares Keep You Up At Night
This article was originally published in The Gray Sheet
Executive Summary
Former CDRH Office of Compliance Director Steve Silverman advises device manufacturers to address two common "quality nightmares": competitors passing them by as they address quality issues and regulatory enforcement actions that can cause them to fall behind other firms. "Good quality doesn't just save device-makers from less-than-baseline compliance; in fact, good quality usually saves money due to fewer compliance deviations," Silverman writes along with his McKinsey & Co. colleagues David Keeling, Enno de Boer and Ted Fuhr in this "Gray Sheet" Medtech Talk column.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.